Skip to content

Enterprise value at other companies

Amgen logo
AmgenAMGN
$246.43B+9.9%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$1.9B+15.2%
Nuvation Bio logo
Nuvation BioNUVB
$1.42B+154%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$452.74M+5.3%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$599.78M-15.4%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$684.98M+89.8%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$684.39M+102%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Calculated from Rigel Pharmaceuticals’s reported figures.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's enterprise value?
Rigel Pharmaceuticals (RIGL) reported enterprise value of $543.41M in Q1 2026.
How has Rigel Pharmaceuticals's enterprise value changed year-over-year?
Rigel Pharmaceuticals's enterprise value increased by 96.3% year-over-year, from $276.89M to $543.41M.
What is the long-term trend for Rigel Pharmaceuticals's enterprise value?
Over 5 years (2020 to 2025), Rigel Pharmaceuticals's enterprise value has grown at a 6.9% compound annual growth rate (CAGR), from $587.45M to $820.29M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.